How to Sell an Imaging Center (2026): Acquisition Multiples, Named Buyers, & Modality Playbook

Quick Answer

Christoph Totter · Managing Partner, CT Acquisitions

M&A advisory across 500+ active capital partners · Healthcare imaging M&A: radiology, MRI, CT, PET · Updated June 6, 2026

In a 2026 imaging center acquisition, a US outpatient center typically sells for roughly 4x to 12x EBITDA per the CT Acquisitions profile ranges on this page, depending on modality mix, payer mix, and operating infrastructure. By profile: a single-site center with basic X-ray and ultrasound at $300k-700k EBITDA goes 4x-6x; a multi-modality single-site or small group with MRI and CT at $1-3M EBITDA goes 5x-8x; a regional multi-site outpatient imaging platform at $5-15M EBITDA goes 7x-10x; a premium scale platform ($15M+ EBITDA, multi-state, hospital-system JVs, advanced modalities including PET/CT and MRI 3T, named in-network commercial contracts, modern PACS/RIS infrastructure) goes 9x-12x+. Active buyers include RadNet (NASDAQ: RDNT, $1.5B+ revenue, the largest US public outpatient imaging operator with 350+ centers primarily in CA/AZ/NY/NJ/MD/DE/FL/TX), Akumin (private, Stonepeak-owned since 2024, acquired Alliance HealthCare Services in 2021 for $820M), SimonMed Imaging (PE-backed, ~170 centers in AZ/CA/FL/NY/NM/MI), US Radiology Specialists (PE-backed by Welsh, Carson, Anderson & Stowe, multi-state via Charlotte Radiology, South Carolina Radiology, etc.), Envision-spinoff radiology, plus PE-backed platforms (Welsh Carson, ABRY Partners, Wellspring Capital, Avista Healthcare Partners, Lee Equity Partners) and hospital-system buyers (HCA, Tenet, Ardent, Universal Health Services, Trinity Health, AdventHealth) acquiring outpatient imaging assets in their footprints. The biggest multiple drivers are payer mix (commercial in-network 50%+), modality mix (MRI/PET > CT > ultrasound/X-ray), CON-state versus open-market dynamics, hospital-system JV opportunities, and modern PACS/RIS with teleradiology partnerships. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.

If you operate an outpatient imaging center or radiology group in 2026, whether that is a single-site MRI center, a multi-modality outpatient group, or a regional multi-site platform, the M&A market is consolidated and capital-deep. RadNet is the public consolidator, Akumin acquired Alliance HealthCare Services in 2021 for $820M, SimonMed and US Radiology Specialists are the PE-backed national platforms, and hospital systems (HCA, Tenet, Ardent, AdventHealth, Trinity, UHS) are selectively buying outpatient imaging as access-point and referral-capture assets.

What the asset is worth depends on three things: (1) modality mix and payer mix (MRI/PET/CT on commercial in-network is the highest multiple; X-ray-only on Medicare PAMA-pressure codes is the lowest), (2) whether you operate in a Certificate-of-Need state and what your CON position is, and (3) the operating infrastructure, PACS/RIS, teleradiology partnerships, advanced-modality capability (MRI 3T, PET/CT, breast tomosynthesis), and hospital-system JV potential. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

Imaging center M&A activity by acquirer (2021-2025)

Related Cluster GuideFor the broader medical-practice sale playbook on how to sell a medical practice, see our companion reference.

The transactions below are public or widely-disclosed deals. They show an active and well-capitalized buyer pool:

The named buyer landscape

Public / strategic buyers

• RadNet (NASDAQ: RDNT, $1.5B+ revenue), the largest US public outpatient imaging operator with 350+ centers primarily in California, Arizona, New York, New Jersey, Maryland, Delaware, Florida, and Texas. Very active tuck-in acquirer and hospital JV partner.
• Akumin (private, Stonepeak-owned since 2024), cross-border imaging operator; acquired Alliance HealthCare Services in 2021 for $820M disclosed.

PE-backed national platforms

• SimonMed Imaging (PE-backed), ~170 centers across AZ/CA/FL/NY/NM/MI.
• US Radiology Specialists (Welsh, Carson, Anderson & Stowe), multi-state platform including Charlotte Radiology, South Carolina Radiology, and other regional radiology groups.
• Outpatient Imaging Affiliates, Vital Imaging, Smart MD Imaging, and other PE-backed and strategic-backed regional platforms.

Hospital systems and IDNs

• HCA Healthcare, Tenet Healthcare, Ardent Health Services, Universal Health Services, Trinity Health, AdventHealth, plus regional health systems, selective acquirers of outpatient imaging in their footprints for outpatient access and downstream referral capture.

PE sponsors active in this space

• Welsh, Carson, Anderson & Stowe, US Radiology Specialists.
• ABRY Partners, Wellspring Capital, Avista Healthcare Partners, Lee Equity Partners, Genstar Capital, multiple healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: commercial in-network status with major payers, advanced modality mix (MRI 3T, PET/CT, breast tomosynthesis, low-dose CT, MRI/MR fusion biopsy), hospital JV potential, modern PACS/RIS (Merge/Sectra/Visage), teleradiology partnerships, CON-state market position, multi-state footprint, audited financials, radiology-group coverage continuity.
• Will compress or reject: heavy Medicare PAMA-pressure routine X-ray/ultrasound mix, single-state CON exposure without growth path, single-payer concentration above 25%, single-referrer concentration above 20%, legacy PACS/RIS, no advanced-modality capability, no teleradiology continuity plan, unaudited financials, open compliance matters.

The operator-level KPI playbook buyers will diligence

Modality and procedure mix

• Modality mix: MRI %, CT %, PET/CT %, ultrasound %, X-ray %, mammography %, DEXA %.
• Revenue per procedure by modality: MRI and PET/CT are highest per-procedure revenue ($600-$2,500+); X-ray and ultrasound are lowest ($50-$200).
• Procedure volume per modality per location: MRI capacity 12-20 scans/day/scanner is operationally healthy; CT 30-50/day/scanner; PET/CT 8-15/day.
• Equipment generation and condition: MRI 3T vs. 1.5T, CT slice count (64-slice min, ideally 128+), age of equipment, service-contract status.

Payer mix and contracting

• Commercial percentage: 50%+ commercial is the platform benchmark.
• Medicare percentage: 30-40% Medicare is healthy; Medicare is structurally pressured (HOPD payment differential vs. office-based) but the volumes are real.
• Medicaid: <15% Medicaid.
• In-network status: Anthem/Elevance, UnitedHealthcare, Aetna, Cigna, BCBS-by-state, plus radiology benefit managers (eviCore, AIM, NIA) prior-authorization workflow integration.
• Single-payer concentration: No single payer above 25%.

Referral source

• Referral source mix: Primary care, orthopedic, neurological, OB/GYN, hospital outpatient, urgent care. Single-referrer concentration risk above 20%.
• Hospital-system relationships: Hospital outreach contracts, JV partnerships, hospital-system referral agreements.
• Self-referral and Stark compliance: Document any physician-investor relationships; Stark-compliant arrangements documented.

Radiology coverage

• Radiology coverage model: In-house radiology group, contracted radiology partner, or teleradiology coverage (vRad, MEDNAX/Pediatrix, Radiology Partners, USARAD, RadiologyTime).
• Subspecialty coverage: Neuro, MSK, body, breast, pediatric, cardiac, subspecialty coverage is a quality and multiple driver.
• Turnaround time (TAT): Routine TAT <24h, STAT <1-4h depending on modality. Track and report.
• Reading errors and peer-review documentation.

Technology and PACS/RIS

• PACS/RIS: Merge (IBM/Watson Health), Sectra, Visage, Intelerad, GE Centricity, Carestream, modern platforms preferred.
• Image-sharing and provider portals: Documented, integrated with referring-physician EMRs.
• Prior-authorization automation: Integration with eviCore, AIM, NIA workflows.
• Patient portal and self-scheduling.

Regulatory and licensing

• Certificate of Need (CON): State-specific. Document CON status for every modality at every facility in CON states.
• ACR accreditation: American College of Radiology accreditation for every applicable modality.
• State licensure: All facilities, all modalities, all current.
• MQSA / mammography certification: FDA / MQSA certification current for mammography.
• Radiation safety officer and dosimetry: Documented compliance.

RCM

• Days in AR: <45 days is healthy.
• Denial rate: <8% first-pass; prior-auth denial rate tracked separately.
• Patient self-pay: Documented financial-assistance, balance-billing compliance, and self-pay collection rates.

Imaging centers for sale: how buyers find and vet them

An imaging center acquisition starts with sourcing: listed centers on business-for-sale marketplaces, centers held by radiology groups or physician owners who never list, and sites shed by hospital systems or larger platforms. Buyers then test equipment, payer contracts, Medicare enrollment, radiologist coverage and any certificate of need before pricing the deal on EBITDA.

Listed imaging centers for sale are mostly small single-site MRI or multi-modality centers. Larger and better-run centers usually change hands privately, through direct approaches to owners, radiology group relationships and buy-side searches. If you are buying, plan for both channels.

• Equipment. Get the age, field strength or slice count, service contract terms and upgrade schedule for every scanner. A center that needs a new MRI soon is worth less than its trailing EBITDA suggests.
• Payer contracts. Confirm which commercial contracts transfer, which must be re-credentialed under a new tax ID, and how long that takes. Revenue can dip during the gap.
• Medicare enrollment. Freestanding centers billing as independent diagnostic testing facilities file with CMS on Form 855B. Plan the change of ownership reporting and supplier standards review before closing.
• Certificate of need. In CON states, confirm each approval transfers with the facility and covers the modalities you plan to run.
• Radiologist coverage. Read the professional services agreement. Know who reads the studies, on what terms, and whether the group can walk after a sale.
• Physician investors. Any referring physician ownership needs Stark and Anti-Kickback review, because it affects both legality and referral volume after closing.

On the sell side, the same checklist tells you what to fix before going to market. CT Acquisitions runs buy-side searches for imaging acquirers and sell-side processes for owners; see our medical practice sale guide for the wider healthcare process.

Dangers and traps in imaging center M&A

1. CON-state exposure without growth path

If you operate in a Certificate-of-Need state (NY, NC, NJ, FL for some modalities, etc.) and your CON portfolio is limited, your growth path is constrained. Document every CON, applicable expansion strategy.

2. Medicare PAMA / HOPD payment differential

Medicare imaging reimbursement is structurally pressured (especially X-ray and routine ultrasound). The HOPD-to-office-based payment differential is the strategic tailwind hospital-acquired imaging benefits from; pure outpatient operators face the lower office-based rates.

3. Single-referrer or hospital-system concentration

If a single referring physician group or hospital-system relationship is 25%+ of revenue, that is a concentration risk that gets repriced. Document long-tenured relationships and look for diversification opportunities.

4. Stark and self-referral exposure

Any physician-investor relationships at the imaging center must be Stark-compliant. In-office-ancillary exceptions, group-practice exceptions, and the related arrangements need documented compliance.

5. Equipment generation and service-contract risk

Aging MRI/CT equipment is a capex liability buyers will model. Document equipment age, service-contract status, and expected replacement timeline.

6. Radiology-group continuity

If your radiology coverage is a contract with an external radiology group that has competing imaging interests or short remaining term, that is a continuity risk. Long-dated coverage agreements with documented subspecialty quality are diligence wins.

7. Prior-authorization compliance and radiology benefit manager (RBM) workflow

eviCore, AIM, NIA prior-authorization workflows must be documented, automated, and clean. Frequent denials or delays raise quality questions.

8. ACR accreditation gaps

Any modality without ACR accreditation triggers diligence questions. Confirm all required accreditations are current.

Our POV on imaging center M&A in 2026

The honest read on the market: outpatient imaging is a mature consolidation play. The public strategic RadNet, Stonepeak-owned Akumin (taken private in February 2024 after a Chapter 11 restructuring, per Akumin court filings), and PE-backed national platforms (SimonMed, US Radiology Specialists, others) are buying selectively, and hospital systems are buying outpatient access strategically.

• If you are a single-site X-ray/ultrasound or simple modality center, multiples are 4x-6x. Buyer pool is regional roll-ups and hospital systems doing geographic tuck-ins.
• If you are a multi-modality single-site with MRI/CT, you are in the tuck-in sweet spot for the national platforms (RadNet, Akumin, SimonMed, US Radiology). Multiples 5x-8x.
• If you are a regional multi-site outpatient imaging platform ($5-15M EBITDA), you are most leveraged. PE sponsors and public strategics will pay 7x-10x in a real competitive process.
• If you are a premium scale platform ($15M+ EBITDA, hospital JVs, advanced modalities, multi-state in-network commercial), you are a strategic target. 9x-12x+ is achievable.

The right time to prepare is 12-18 months before going to market, lock in radiology-group coverage, confirm ACR accreditation, document CON portfolio, modernize PACS/RIS, and structure any hospital JV optionality. Quality compounds in this market.

Preparing your imaging center for sale: 12-18 months out

1. Get multi-year audited or reviewed financials. Cleanly break out revenue by modality, payer, and referrer.
2. Lock in radiology-group coverage. Long-dated coverage agreements with subspecialty coverage and quality metrics are diligence wins.
3. Confirm ACR accreditation and state licensure cleanliness. Every modality, every facility, every state.
4. Document CON portfolio. Every CON, every state, every modality, every expansion opportunity.
5. Modernize PACS/RIS. Migrate to Merge/Sectra/Visage/Intelerad/GE/Carestream modern platforms if you are on legacy.
6. Document Stark compliance. Any physician-investor or referring-physician relationship documented as Stark-compliant.
7. Build advanced-modality capability. MRI 3T, PET/CT, breast tomosynthesis, low-dose CT, each adds to the multiple if utilization supports.
8. Structure hospital JV optionality. If you are not in a hospital JV, explore the JV model with regional health systems pre-sale.
9. Diversify payer and referrer concentration. No single payer or referrer above ~20-25%.
10. Run a competitive process. RadNet, Akumin, SimonMed, US Radiology Specialists, hospital systems in your footprint, and PE sponsors directly (Welsh Carson, ABRY, Wellspring, Avista, Lee Equity), a real auction is worth 1-3 turns of EBITDA over single-bidder negotiation.

The five pillars of how CT Acquisitions works

About the Author

Christoph Totter is the founder of CT Acquisitions, an M&A advisory firm working both sides of the table, headquartered in Sheridan, Wyoming. We work directly with 500+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest consolidators that other intermediaries cannot access. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Connect on LinkedIn · Get in touch

Frequently asked questions

What is the typical multiple for an imaging center in 2026?

Single-site X-ray and ultrasound centers typically sell at 4x-6x EBITDA. Multi-modality single-site or small group with MRI and CT goes 5x-8x. Regional multi-site outpatient imaging platforms ($5-15M EBITDA) go 7x-10x. Premium scale platforms ($15M+ EBITDA, hospital JVs, advanced modalities including PET/CT and MRI 3T, multi-state in-network commercial contracts, modern PACS/RIS) reach 9x-12x+.

Who are the active buyers of imaging centers right now?

Public/strategic: RadNet (NASDAQ: RDNT, $1.5B+ revenue, 350+ centers), Akumin (private, Stonepeak-owned since 2024, $820M Alliance HealthCare Services acquisition 2021). PE-backed platforms: SimonMed Imaging (~170 centers), US Radiology Specialists (Welsh, Carson, Anderson & Stowe). Hospital systems: HCA, Tenet, Ardent, AdventHealth, Trinity, UHS. PE sponsors directly: Welsh Carson, ABRY Partners, Wellspring Capital, Avista Healthcare Partners, Lee Equity Partners, Genstar Capital.

What hurts an imaging center’s valuation most?

Heavy Medicare PAMA-pressure routine X-ray/ultrasound mix, single-state Certificate of Need exposure without expansion path, single-payer concentration above 25%, single-referrer concentration above 20%, legacy PACS/RIS, no advanced-modality capability, no teleradiology continuity plan, Stark or self-referral compliance issues, ACR accreditation gaps, and aging MRI/CT equipment without service-contract status.

What is CON and why does it matter?

Certificate of Need is state-level regulation requiring approval before adding new imaging modalities, facilities, or capacity. CON states (NY, NJ, NC, FL for some modalities, etc.) constrain new-entrant competition; if you operate in a CON state, your CON portfolio is part of the valuation. In non-CON states, the market is more competitive but expansion is faster.

How important is hospital JV potential?

Increasingly important. RadNet’s hospital-system JV strategy has been a multi-year growth driver. Hospital systems get outpatient access and downstream referral capture; the operator gets infrastructure, referral volume, and payer leverage. Pre-sale structuring of hospital JV optionality is a real multiple-builder.

Do I have to pay a broker fee?

It depends on the mandate. CT Strategic Partners runs an M&A advisory model. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.

How long does it take to sell an imaging center?

Once you go to market with an M&A advisor, a typical process runs 5-8 months from initial outreach to closing. Add 12-18 months of preparation work before going to market (radiology-group coverage lock-in, ACR accreditation, CON portfolio documentation, PACS/RIS modernization).

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. That gives time to lock in radiology coverage agreements, confirm ACR accreditation, document Stark compliance, modernize PACS/RIS, structure hospital JV optionality, diversify payer and referrer concentration, and build the management bench.

Can a physician own an imaging center?

Yes, but federal Stark law treats MRI, CT, PET and other imaging as designated health services, so a physician generally cannot refer Medicare or Medicaid patients to a center they own unless an exception applies, such as the in-office ancillary services exception within a group practice. The Anti-Kickback Statute and state self-referral laws add further rules, so have healthcare counsel review any physician-investor structure.

Who owns imaging centers in the US?

Ownership is mixed. RadNet is the largest public outpatient imaging operator. PE-backed platforms such as SimonMed, US Radiology Specialists and RAYUS Radiology own many centers, hospital systems run their own sites and joint ventures, and radiology groups and independent physicians still own a large share of single-site centers. That mix is why both strategic and financial buyers compete for well-run centers.

Related research

• How to sell a clinical laboratory
• How to sell an urgent care center
• How to sell an infusion therapy business
• How to sell a DME business
• How to sell a physical therapy practice
• How to sell a medical billing company
• How to sell a home health agency
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative